ScripsAmerica (OTCBB: SCRC) is a competitive provider of pharmaceutical supply chain management. Our low-cost marketing, sales, and distribution capabilities of prescription and OTC drugs has made us competitive in the United States.
Our competitive pricing, client retention rates and strong relationships throughout the pharmaceutical distribution chain have positioned us to efficiently acquire clients and provide competitive service in an increasingly complex marketplace.
Brian Ettinger –Chief Executive Officer
CHIEF FINANCIAL OFFICER
A creative, results-oriented problem solver with a background in financial accounting, Mr. Andrews has served companies in the manufacturing, distribution, technology, consulting, construction, and service industries. His professional experience includes tenure as Chief Financial Officer for Global Resource Corporation, Judge Information Management Solutions, and The Judge Group; Controller of Encapsulation Systems, Goodwin Pumps of America, Morris Wheeler & Co., and Mater Burt Co.; Audit Manager of Stockton Bates/Gold & Co., C.P.A.; and as Manager of Ernst & Young’s Special Services Group. After joining ScripsAmerica in September 2010, Mr. Andrews took responsibility for the overall financial management of the Company, financial reporting and transparency, and for corporate functions including controller, treasury, investor relations, long-range planning, and corporate and strategic development. Mr. Andrews earned a B.S. in Accounting from Villanova University, is a Certified Public Accountant in the Commonwealth of Pennsylvania, and a member of both the American Institute and the Pennsylvania Institute of Certified Public Accountants.
Brian Ettinger -Chairman
Mr. Ettinger is the founder of Law Office of Brian Ettinger, a law firm concentrating on a general practice emphasizing Civil Litigation, Business Litigation, International Business Contracts and Negotiations including Energy Related Industries. He previously has served as Chairman of the Board of Global Resource Corporation, oversaw shareholder issues, Board of Director Committees, and meetings. He participated at the request of management in capital raises, contract negotiations, and business operations. He also served as in-house legal counsel at the request of management. Brian brought Schlumberger to the company to enter into a joint development agreement to develop technologies utilizing microwave frequencies for extraction of heavy oil and tar sands. He assisted in handling negotiations on this transaction. He also assisted in negotiations on the license agreement entered into with Universal Alternative Fuels. He is currently General Counsel and CEO of Worldwide Strategic Partners Inc., an energy consulting firm involved in domestic and international energy projects involving oil and gas production, exploration, alternative fuels, waste to energy, biofuels, power, and pipelines. He received his B.A. degree from LaSalle College and JD Degree from South Texas College of Law.
Dr. Joseph Camardo is Senior Vice President for Global Medical Affairs at Celgene Corporation in Summit, NJ. Dr. Camardo received a Bachelor of Arts degree in Biology from the University of Pennsylvania in Philadelphia in 1974, and an MD from the University Of Pennsylvania School Of Medicine in 1979. He completed his internship at the Hospital of the University of Pennsylvania in 1980, and his residency at Presbyterian Hospital in Philadelphia in 1988. Between his internship and residency Dr. Camardo worked as a postdoctoral fellow at the Division of Neurobiology and the Department of Pharmacology at the College of Physicians and Surgeons of Columbia University in New York. His laboratory work on the molecular basis of synaptic plasticity led to the isolation of a new potassium channel that was demonstrated to be a key intermediary molecular in the development of learning and memory. He also worked on the isolation of the sodium channel in heart muscle, and was among the first to isolate and characterize the sodium channel using single channel recording techniques. Dr. Camardo was a fellow at the Universidad Central de Venezuela, working in the cardiology division on a program to evaluate the arrhythmias that occur in patients with Chagas disease. Dr. Camardo is Board Certified in Internal Medicine, and licensed to practice in Pennsylvania and New York. He is a Fellow of the College of Physicians of Philadelphia.
Dr. Imperiale has been with Bio Marin as the Senior Director, Global Medical Affairs from 2009 to the present, and the medical lead for all commercial programs. He maintains global responsibility for Naglazyme, Kuvan, Aldurazyme, and Firdapse, and is a Member of the Brand team and Core team for Naglazyme and Kuvan. Dr. Imperiale conducted the clinical portion of the Pre IDE meeting with the FDA and was responsible for the following divisions: Medical information; Investigator relations; Medical Writing; and Scientific Affairs. Prior to Bio Marin, he worked as the Vice President of Clinical Research Operations at Hana Biosciences from 2007-2009 and was the medical lead and strategist for all their clinical programs. He also has experience working at Exelixis as the Director of their Clinical Trials Development where he was esponsible for medical FDA filings, external investigator relationships, medical management of Oncology and Nephrology Clinical Trials, and establishment of Clinical Advisory Boards. He is a graduate of Villanova University and Hahnemann University School of Medicine.
Mr. Lewis currently serves as the CEO, CFO and Chairman of the publicly traded company Paid Inc. (PAYD). Additionally, he serves as a member of the Board of Directors for MAM Software Group, Inc. (MAMS) as well as Viryanet (VRYAF). Since 2004, Mr. Lewis has also served as Chief Executive Officer of Lewis Asset Management Corporation, an investment management company that he founded, as well as the Portfolio and Chief Investment Officer of the company’s Lewis Opportunity Fund.
Prior to founding Lewis Asset Management, Austin Lewis held a variety of positions with investment firms including Puglisi & Co., Thompson Davis & Co., RBC Capital, Tucker Anthony and Branch Cabell & Company. He holds a Bachelor of Science in Finance and a Bachelor of Science in Financial Economics from James Madison University.
Mr. Pranskevicius is recognized as a leader with strength in developing new business ideas, expansion and diversification. In managerial positions he has achieved significant improvements in business strategy, reengineering business processes and building powerful teams. Mr. Pranskevicius manages Development 72 LLC, a private equity holding company focused on acquiring high-potential companies in the Healthcare, Information Technology, and Fast-Moving Consumer Staples industries. Mr. Pranskevicius funded ScripsAmerica with $1.1 mil in April 2011 followed by $500,000 in 2012 and a purchase order line of credit of an additional $500,000. Mr. Pranskevicius has 12 years of experience on an international level in investment management, finance, real estate, grocery and fast food businesses. Mr. Pranskevicius specializes in value-added investments and partnering with existing management to realize long term results. Mr. Pranskevicius is an experienced member of the board in Semiconductor, Healthcare, Consumer Good, Fast Food, Food Processing and Start-Up companies. He received his Bachelor degree in Business administration and Management, Vilnius University, Lithuania and is currently attending Hough Graduate School of Business at University of Florida for his M.B.A.
Pelligrino L. Certa
Mr. Certa is an attorney licensed in Pennsylvania, New York and Washington State whose primary practice is personal injury law. In 2006, he founded the Certa Law Group, of which he is currently the President and Managing Attorney. The Certa Law Group has offices in Pittsburgh, Pennsylvania and Seattle, Washington. More recently he has established two (2) additional practices in Pittsburgh: Pittsburgh Bike Law (2015 – present) and Accident & Injury Law Group (2016 – present).